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Abstract 
Background: Systemic lupus erythematosus (SLE) is an autoimmune disease that is 
characterized by T-cells imbalance. There are ongoing controversies about the role of 
specific T-helper cell subsets and their cytokines. The study aimed to confirm the 
disturbance of Th17/Treg ratio in SLE patients. 
Methods: Subjects were SLE patients who met the American College of Rheumatology 
1997 criteria. Disease activity assessment was measured by SLAM index. Th17 and Treg 
level was measured by flow cytometry. Th17 level was evaluated as CD4
+
L17 whilst Treg 
as CD4
+
Foxp3
+
. Final result is stated as Th17/Treg ratio. 
Results: Thirty female subjects with active SLE had mean SLAM Score of 29.3±3.88, C3 
level 25.2 (6-59.5), C4 level 15.25 (5-54.3), ESR 62.1±37.85, CRP 30.16±59.45, and anti-
dsDNA 155.32±186.10. Higher Th17 level was found in SLE patients compared to healthy 
subjects (30.09 pg/ml vs 13.01pg/ml; 12.60% vs 0.91%). However, it did not correlate to 
disease activity (p>0.05; r=-0.28). Regarding Treg level, there was no significant 
difference between active SLE and healthy subjects (12.85 vs 11.05 pg/ml; 9.57% vs 
2.05%). Treg level negatively correlated to SLE disease activity (p<0.01; r=-0.73). 
Th17/Treg ratio was 3.28±2.22% and it positively correlated to SLE disease activity 
(p<0.01; r=0.78). 
Conclusion: Th17/Treg ratio is positively correlated with disease activity. Th17 level is 
elevated but not correlated with disease activity. Decrease of Treg level is not significant 
though correlated with disease activity in SLE patients. 
Keywords: Systemic Lupus Erythematosus, disease activity, Th17, Treg, Th17/Treg ratio 
 
Citation: 
Yuliasih Y, Diah Rahmawati L, Maulidya Putri R Ratio of Th17/Treg and Disease Activity in 
Systemic Lupus Erythematosus. Caspian J Intern Med 2019; 10(1): 65-72. 
 
 
Systemic lupus erythematosus (SLE) is an autoimmune disease that is triggered by 
overly activated autoantigen-specific T cells and characterized by the presence of multiple 
autoantibodies in target organs (1, 2). These antibodies are end-results of the apoptotic 
program impairment and the decrease of apoptotic material clearance. The apoptotic 
materials, including the immunogenic modified histones in particular, are captured by 
antigen presenting cells (APC) then presented to T-cells. This reaction consequently leads 
to T-cells hyper-responsiveness and immune complex, causing inflammation and organ 
damage (3-5). New studies at cellular level have shown that homeostasis disturbance 
between Effector T-cells (Th) and Regulator, T-cells (Treg) contribute significantly to the 
pathogenesis of SLE. This new paradigm is slowly replacing the old one about the roles of 
B-cells and Th1/Th2 in SLE pathogenesis. There are many recent studies that have been 
reported that Th17 cells produce several pro-inflammatory cytokines, such as IL-17A, IL-
17B, and IL-22, which can cause tissue injury and eventually organ damage.  
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IL-17 level is abnormally high in active SLE patients. 
Thus, the higher IL-17 level found in SLE patient, more 
organ damage occurs (6-9). Treg stimulates IL-2 and TGF-β, 
which have protective effects in autoimmune disease. Treg 
function is interfered by IL-6. The elevation of IL-6 level in 
SLE converts Treg to Th17 (10). The mechanism of 
suppression by Treg is classified into 4 mode of actions: 
inhibitory cytokines, cytolysis, metabolic disruption, and 
targeting dendritic cells. Treg secretes inhibitory cytokines 
IL-10, IL-35, and TGF-β which directly inhibit effector T 
cells (Th) activity (11). The imbalance of immunogenic 
tolerance of dendritic cells limits the expansion of Treg and 
causes a lower Treg cells level. Both Treg level and function 
are imperative in pathogenesis and activity of SLE.  
Compared to Treg, Th17 levels are essentially higher in 
the early stage of SLE. This imbalance is deemed to be 
connected to the disease activity of SLE itself, which can be 
measured by a valid (0.9) and reliable (0.83) scoring system 
like Systemic Lupus Activity Measure (SLAM) index. 
SLAM index is applicable for SLE patients who have not 
undergone treatment using immunosuppressive agents (9, 12, 
13). It is suitably used in this study, considering most of SLE 
patients in Dr. Soetomo General Hospital Surabaya are 
referred by secondary health care yet untreated. Our previous 
study reported that the mortality rate of SLE patients 
admitted to Dr. Soetomo General Hospital in 2004 was 
22,9% (14). It was significantly higher than global mortality 
rate for SLE (0,025%) (15). Hence, early evaluation of Th17 
and Treg level is very crucial in order to take immediate 
intervention, to improve prognosis, and to suppress mortality 
in SLE patients. This study aims to evaluate Th17 cells and 
Treg level and to confirm the association of Th17/Treg ratio 
with disease activity in patients with active SLE. 
 
 
Methods 
Subjects and Sampling Method: This study was approved 
by the Ethics Committee of Dr. Soetomo General Hospital 
for human research number 155/Panke. KKE/III/2017 and 
informed consent was obtained from all participants. 
Subjects in this study were enrolled using consecutive 
sampling method. Sample size was determined by the 
following formula (16).   
The subjects were thirty female patients with active SLE 
who matched the revised American College of 
Rheumatology 1997 (ACR) SLE criteria and had an active 
disease characterized by Systemic Lupus Activity Measure 
(SLAM) index > 20. Based on a previous study, higher than 
20 SLAM index indicates highly active SLE. These patients 
were hospitalized in the Internal Medicine ward, Dr. 
Soetomo General Hospital, Surabaya, Indonesia. All SLE 
patients in this study were females, considering the number 
of SLE case from Indonesian female population is 40 times 
higher than male population (14). Patients with infections, 
steroid or immunosuppressant medications, malignancies, 
history of smoking, acute coronary syndrome, tuberculosis, 
HIV/AIDS, and inflammatory bowel disease were excluded 
from this study. Four healthy subjects were also recruited 
and had their Th17 and Treg level tested as baseline.  
SLAM Index Scoring: SLAM index was introduced in 1988 
by Liang et al. It consists of 31 items to evaluate clinical 
symptoms and laboratory findings and to review 11 system-
organs using 1-3 scoring system. The total score depends on 
the severity of organ damage, ranging from 0 to 86 points. 
The higher the score implies more active disease. The 
sensitivity of SLAM index compared to SLEDAI/BILAG are 
identical, despite Petri et al. (2005) mentioned that SLEDAI 
is the most sensitive (2). However, considering the wide 
range of SLEDAI scoring system (1 to 8) which can easily 
cause scoring bias between different examiners, SLAM 
index is more suitable for this study as the scoring scale is 
only ranged from 1 to 3.  
PBMCs Isolation: In order to optimally analyze Th17 and 
Treg using flow cytometry, T-cells specimen was obtained 
by isolating mononuclear white blood cells (lymphocyte and 
monocyte) from peripheral blood. Peripheral blood 
mononuclear cells (PBMCs) are separated from 4 ml of 
heparinized venous blood by a density gradient 
centrifugation method using Ficoll Histopaque.  
Stimulation of the cells: Normal PBMCs were stimulated in 
media for 5 hours using PMA/Ionomycin (at 50 ng/ml and 
1μg/ml respectively for 1 million cells) in the presence of 
BD GolgiStop™ protein transport inhibitor (Cat No. 
554724). 4 μl of BD GolgiStop™ was added for every 6 ml 
of cell culture and mixed thoroughly. BD GolgiStop™ 
should not be kept in the culture for longer than 12 hours.  
Staining of the cells: Cells were collected in vitro using a 
protein transport inhibitor, centrifuged (250 x g) out of the 
medium containing BD GolgiStop™, and suspended in BD 
Pharmingen™ Stain Buffer (FBS); Cat No. 554656. Cells 
were counted and adjusted with concentration to 20 million 
cells/ml in stain buffer (FBS). Cells were fixated gently by 
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re-suspending a pellet of 1 million cells in residual volume 
of wash buffer and adding 2ml of 1x human FoxP3 buffer A. 
Afterwards, cells were incubated for 10-20 minutes at RT in 
the dark and centrifuged 500 x g for 5 minutes, and then got 
the fixative removed. Cells were then washed and each pellet 
was re-suspended in 2ml of stain buffer (FBS), and 
centrifuged 500 x g for 5 minutes. Lastly, the buffer was 
removed and cells were stored or preceded to 
permeabilization of cells. 
Permeabilizing the fixed cells: DMSO was removed from 
frozen cells by washing twice with 2 ml/tube of stain buffer 
(FBS) and centrifuged 500 x g for 5 minutes at RT, got the 
buffer removed and washed again. Cells were permeabilized 
gently by suspending the pellet in residual volume of buffer 
and then adding 0.5 ml of 1x working Human FoxP3 Buffer 
C solution to each tube. 
 Next, cells were incubated for 30 minutes at RT protected 
from light and washed twice with 2 ml/tube of stain buffer 
(FBS), centrifuged 500 x g for 5 minutes at RT and got the 
buffer and stain removed. 
Staining with the cocktail: Cells were thoroughly 
suspended and fixed/permeabilized in 50 μl -150 μl of stain 
buffer (FBS) and added 20 μl/test of cocktail or appropriate 
negative control. Next, cells were incubated at RT for 40 
minutes in the dark and should be protected from light 
throughout staining and storage. Afterwards, cells were 
washed twice with 2 ml/tube of stain buffer (FBS), 
centrifuged 500 x g for 5 minutes at RT and got the buffer 
removed then analyzed. 
Flow cytometry analysis: Flow cytometry analysis was 
performed to measure Th17 and Treg percentages using 
human Th17/Treg phenotyping kit (BD Biosciences, Texas, 
USA) and Becton & Dickinson Flow Cytometry. Both of 
these cells were measured from PBMCs of the SLE patients 
and controls.  
Cells were fixed and permeabilized with Fix/Perm buffer 
(BD Bioscience, USA). Afterwards, cells were labeled with 
PEanti-human IL-17A (BD Bioscience, USA) for Th17 
identification and FITC anti-human CD4 antibody/PerCP 
anti-human FoxP3
+
 antibody (BD Bioscience, USA) for Treg 
identification. Flow cytometry was analyzed using BD 
CellQuest Pro software (BD Bioscience, USA). 
Statistical analysis: All collected data were arranged in 
tabular form and processed statistically using the SPSS 21.0 
program (IBM Corp., Armonk, NY, USA). Test of data 
normality was analyzed using Shapiro-Wilk normality test. 
The correlation between the Th17/Treg ratio and disease 
activity was analyzed using Pearson’s correlation coefficient 
test (for normal distribution) or Spearman’s rank correlation 
coefficient test (for abnormal distribution); A p<0,05 was 
considered statistically significant. 
 
 
Results 
Demography and clinical characteristics of the subjects: 
Thirty female patients with active SLE had their SLAM 
index scored and resulted with 29.3±3.88. The mean age of 
SLE patients in this study was 31.3±10.5 years old. Most of 
subjects were anemic with serum hemoglobin level of 
7.12±2.32. ESR level was at 62.1±37.85 and considered as 
high. Both C3 and C4 level were low, at 25.2 (6-59.5) and 
15.25 (5-54.3) respectively.  
High level of anti-dsDNA was found at 155.32±186.1. 
The clinical information and the laboratory results of the 
subjects are shown in table 1.  
 
Table 1. Clinical information and laboratory results of 
the subjects 
 
Characteristics Total (n = 30) 
Sex (Female/Male) 30 : 0 
Age (years) (Mean ± SD) 31.3 ± 10.5 
Hemoglobin (Mean ± SD) 7.12 ± 2.32 
Lymphocyte (Mean ± SD) 967.87 ± 427.78 
Thrombocyte (Mean ± SD) 212766.67 ± 206889.06 
ESR (Mean ± SD) 62.10 ± 37.85 
CRP (Mean ± SD) 30.16 ± 59.45 
C3 (Median)  25.20 (6.00–59.50) 
C4 (Median) 15.25 (5.00–54.30) 
anti dsDNA (Mean ± SD) 155.32 ±186.10 
 
Table 2 shows the distribution of clinical and laboratory 
manifestations according to ACR 1997 criteria. The most 
common manifestation was arthritis (76.7%). Renal disease 
and neurological disorder were diagnosed in 50% and 20% 
of the subjects, respectively. Hematological manifestations 
were found in all subjects: 66.7% with hemolytic anemia, 
3.3% leukopenia, 90% lymphopenia, and 40% with 
thrombocytopenia.  
In this study, ANA test was found positive in 73.3% 
subjects and followed by 46.7% subjects with positive anti-
dsDNA.  
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Table 2. Clinical manifestations of the subjects according 
to ACR 1997 criteria 
ACR 1997 characteristics 
Percentage 
(%) 
Malar rash 13.3 
Discoid rash 26.7 
Photosensitivity 43.3 
Oral ulcer 33.3 
Arthritis 76.7 
Serositis 46.7 
Renal disease 50.0 
Neurologic disorders 20.0 
Hematologic disorders 
Hemolytic anemia with reticulosis 
Leukopenia < 4000/mm3 
Lymphopenia < 1500/mm3 
Thrombocytopenia < 100×103/mm3 
 
66.7 
3.3 
90.0 
40.0 
Immunologic disorders 
Anti-dsDNA positive 
Anti-Sm positive 
Anti-phospholipid positive 
 
46.7 
23.3 
0 
ANA test positive 73.3 
 
Th17 and Treg level in patients with active SLE: The 
measurement of Th17 and Treg levels was performed by 
analyzing PBMCs using flow cytometry. All dots captured in 
a form of scatter diagram by either forward or side scatter 
represent the whole leukocytes (granulocytes, lymphocytes, 
and monocytes). CD4 lymphocytes expressed both IL-17A 
and Foxp3 plotted within gating area (R1) which were then 
processed and analysed separately (Fig. 1). Th17 cells 
expressed CD4+ IL-17+, whereas the Treg cells expressed 
CD4+FoxP3+. Th17 level in active SLE patients was 
30.09±12.60% (fig.2a) with baseline level of 13.01±0.91% 
in healthy subjects. Treg level was 12.85±9.57% (fig. 2b),  
 
which showed no difference compared to healthy subjects 
(11.05±2.05%). Additionally, we found that the subjects’ 
Th17/Treg ratio was also higher (3.82±2.22) compared to 
that of the healthy subjects’ (1.20±0.20) (fig. 2c).  
Th17 correlation to disease activity in patients with active 
SLE: A correlation of Th17 cells to disease activity is shown 
in fig. 3a. Th17 serum level (CD4+IL-17) and SLAM score 
were analyzed by Pearson’s correlation test and the result 
shows that it has no correlation to SLE disease activity (r=-
0.277, P=0.138). This study also analyzed Th17 level’s 
correlation to hemoglobin and lymphocyte (using Pearson’s 
correlation test) and to proteinuria (using Spearman’s 
correlation test). Th17 level was found to have a correlation 
with hemoglobin level (r=507, P=0.004). However, it does 
not correlate to lymphocyte count (r=-0.261, P=0.164) and 
proteinuria (r=-0.200, P=0.289). 
Treg correlation to disease activity in patients with active 
SLE: Spearman’s rank correlation test was used for 
correlation analysis between Treg serum level 
(CD4+Foxp3+) and SLAM score in total SLE patients. As 
shown in fig. 3b, Treg serum level has a strong inverse 
correlation to SLE disease activity (r=-0.728, P=0.000). 
Th17/Treg ratio correlation to disease activity in patients 
with active SLE: Pearson’s correlation test was used for 
analysis between Th17/Treg ratio and SLAM score in each 
SLE patient. In fig.3c, correlation analysis shows that there 
is a strong correlation between Th17/Treg ratio with SLE 
disease activity (P=0.000, r=-0.728). This study also 
analyzed the correlation of Th17/Treg ratio to ESR, CRP, 
C3, C4, and anti-dsDNA, in which the correlations were 
found only for C3 (r=-0.69, p<0.01) and C4 (r=-0.52, 
P=0.52, p<0.01). 
   
 
 
 
Figure 1. Flow cytometry analysis of CD4 expressing IL-17A and Foxp3 
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Figure 2. Th17 and Treg level measured from subjects’ peripheral blood mononuclear cells (PBMCs). A. Subjects’ Th17 
mean level. B. Subjects’ Treg mean level. C. Subject’s Th17/Treg mean ratio. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Correlation between Th17, Treg, and Th17/Treg ratio from subjects’ peripheral blood mononuclear cells 
(PBMCs) and disease activity. A. Th17 level vs. SLAM. B. Treg level vs. SLAM. C. Th17/Treg ratio vs. SLAM 
 
Discussion 
In this study, all subjects were productive young women 
who presented high SLE activity confirmed by SLAM index, 
complement level, ESR, and CRP. We expected lower Treg 
level and elevated Th17/Treg ratio occurs in active SLE 
patients. Our results showed that higher Th17 level, lower 
Treg level, and higher Th17/Treg ratio were found in SLE 
patients compared to healthy patients. It was consistent to 
previous studies involving active SLE subjects. Our results 
also confirmed that Treg level has an inverse correlation with 
disease activity measured by SLAM index, whilst Th17/Treg 
ratio shows a strong correlation to disease activity. 
Elevated Th17 level was found in active SLE patients. 
According to past studies, Th17 and IL-17 have a significant 
role in SLE progression and are found higher in active SLE 
compared to inactive SLE (17, 18). We observed no such 
correlation exists between Th17 level and disease activity,  
 
 
despite several studies claimed for their linear correlation. 
The explanation to this finding is that IL-7 might correlate to 
disease severity instead of disease activity. Th17 are able to 
secrete tumor necrosis factor (TNF), IL-2, and IFN-γ (10, 
19). Based on this theory, in patients with SLE (including 
new-onset disease), elevated Th17 and IL-17 levels increase 
their infiltration ability to target organs (6).
  
High Th17 level 
in SLE patients results in excessive production of pro-
inflammatory cytokines and chemokines, so that the 
systemic condition of SLE patients will always be in an 
inflammatory state, causing more severe inflammation and 
organ failures, especially renal and hematological 
impairments. The presence of kidney and hematological 
impairments is a sign of a severe lupus. Our previous study 
observed a high mortality rate caused by renal and 
hematological impairments in Dr. Soetomo General Hospital 
A B 
A B 
 
C 
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Surabaya (14). As for the non-correlating Th17 and 
proteinuria, it might be due to small sample size of this 
study. 
Yang et al. found that Th17 level in SLE patient was 
correlated to disease activity and its level would increase 
during lupus flare and decrease after treatment (17). Zickert 
et al. (2015), Kwan et al., 2009, also reported that IL-17 was 
related to the activity of lupus nephritis. IL-17 was found 
abundantly in lupus nephritis (LN) patients, although 
molecular mechanism which explains T-cells or IL-17 
dependent tissue damage of LN was not clearly elaborated. 
There are some findings that demonstrated the contribution 
of T-cell signaling pathways to the expression of LN (20). 
High IL-17 baseline can predict unfavorable histopathology 
response. IL-17 is also responsible in aplastic anemia (21). 
Our study demonstrated that there was no substantial 
decrease of Treg level in SLE patients. Previous studies 
provided inconsistent evidence; some stated the decrease 
Treg level (22), others declared its similarity with healthy 
patients (23) or even elevated Treg level (24). Our results 
might be explained by other studies that mentioned the 
decreasing function of Treg in SLE without the decreased 
level in peripheral blood (25). This variant might be caused 
by different methods of isolation used in this study and 
subjects’ various characteristics, considering the lack of 
consensus for Treg phenotyping method in human (26). This 
study showed a slight elevation of Treg compared to healthy 
subjects. The elevation could be caused by mixed activated 
T-cells during the counting in which T-cells can adaptively 
convert to Treg (27). Another plausible explanation is that 
Treg might attempt to control the exacerbated immune 
response in active disease (28). 
In association with disease activity in our study, Treg had 
a significant inverse correlation. These findings were in 
accordance to a study by Maraghy et al., (2016) in which 
Treg had a significant correlation with renal impairment and 
hematological impairment (28). Treg CD4+Foxp3 secretes 
an abundant amount of cytokines that proliferate CD4 T-
cells specific towards nuclear antigen, such as nucleosome, 
which is known as pathogenic antibody in lupus nephritis 
(29). Antibody nucleosome level is higher in lupus with 
renal impairment. Decrease of Treg correlates with disease 
severity (30). A study by Shakweer et al., (2016) showed the 
elevated Foxp3+ expression in non-proliferative lupus 
nephritis compared to the proliferative one (31). CD4+Foxp3 
without CD25 expression is an important subset from 
Foxp3+ T cells that has been found frequently in SLE 
patient. CD4+Foxp3 may be distinctive in SLE but the origin 
and function of this subset of Treg are mostly unknown (29). 
Furthermore, our study found a correlation between 
Th17/Treg ratio and disease activity of SLE. This study 
confirmed that Th17/Treg ratio could be used to differentiate 
active and inactive SLE, as well as its severity (32). The 
greater ratio represents higher and more severe disease 
activity. We also analyzed the correlation between 
Th17/Treg ratio and certain laboratory parameters frequently 
used in daily practice to determine severity of disease, such 
as ESR, CRP, C3, C4, and anti-dsDNA. We observed that 
there was a significant inverse correlation between 
Th17/Treg ration with both C3 and C4. This finding 
successfully confirmed a study by Narayanan et al., (2011) 
and Bahlas & Damiati (2014) (33).  
According to Lam & Petri (2005), a measurement of C3 
and C4 level is helpful for diagnosing SLE, although 
hypocomplementemia is not specific for SLE. On the other 
side, no correlation was found for ESR, CRP and anti-
dsDNA levels. ESR measurement has many limitations and a 
low diagnostic value. It is only useful for treatment response 
evaluation (2). Cengic et al. (2002) mentioned that ESR and 
CRP levels are to evaluate the relapse of the disease and to 
distinguish infection (34). Most of the previous studies tried 
to correlate anti-dsDNA level to disease activity, but their 
findings showed inconsistencies (33, 35). The number of 
SLE patients with positive anti-dsDNA in our population is 
considerably low. Thus, it might affect the result of our 
study. All subjects in this study were under the Indonesian 
government’s health insurance. However, several 
examinations were not fully covered. 
In conclusion, elevated Th17 level and insignificant 
decrease of Treg level, and Th17/Treg ratio correlate to 
disease activity and disease severity in patients with active 
SLE. Elevated Th17 level significantly contributes to chronic 
inflammation process in SLE. Imbalance of Th17/Treg ratio 
is an important determinant for SLE disease activity and 
disease severity. 
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